IL301140A - Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection - Google Patents
Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infectionInfo
- Publication number
- IL301140A IL301140A IL301140A IL30114023A IL301140A IL 301140 A IL301140 A IL 301140A IL 301140 A IL301140 A IL 301140A IL 30114023 A IL30114023 A IL 30114023A IL 301140 A IL301140 A IL 301140A
- Authority
- IL
- Israel
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence
- cdr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246113P | 2015-10-25 | 2015-10-25 | |
| EP16305211 | 2016-02-24 | ||
| US201662322029P | 2016-04-13 | 2016-04-13 | |
| US201662331169P | 2016-05-03 | 2016-05-03 | |
| PCT/US2016/058540 WO2017074878A1 (en) | 2015-10-25 | 2016-10-24 | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL301140A true IL301140A (en) | 2023-05-01 |
Family
ID=55588187
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301140A IL301140A (en) | 2015-10-25 | 2016-10-24 | Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection |
| IL258822A IL258822B2 (en) | 2015-10-25 | 2018-04-22 | Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL258822A IL258822B2 (en) | 2015-10-25 | 2018-04-22 | Trispecific and/or terrivalent binding proteins for the prevention or treatment of HIV infection |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20190054182A1 (enExample) |
| EP (2) | EP3365366B1 (enExample) |
| JP (3) | JP7169190B2 (enExample) |
| KR (1) | KR102687212B1 (enExample) |
| CN (4) | CN117069855A (enExample) |
| AR (1) | AR106466A1 (enExample) |
| AU (2) | AU2016347058B2 (enExample) |
| BR (1) | BR112018008011A2 (enExample) |
| CA (1) | CA3002664A1 (enExample) |
| CL (1) | CL2018001065A1 (enExample) |
| CO (1) | CO2018005337A2 (enExample) |
| CR (1) | CR20180288A (enExample) |
| DO (1) | DOP2018000102A (enExample) |
| EA (1) | EA201891028A1 (enExample) |
| ES (1) | ES2894304T3 (enExample) |
| HR (1) | HRP20211528T1 (enExample) |
| HU (1) | HUE056608T2 (enExample) |
| IL (2) | IL301140A (enExample) |
| MA (1) | MA42641A1 (enExample) |
| MX (2) | MX2018005048A (enExample) |
| MY (1) | MY192278A (enExample) |
| PE (1) | PE20181167A1 (enExample) |
| PH (1) | PH12018500873A1 (enExample) |
| PL (1) | PL3365366T3 (enExample) |
| RS (1) | RS62437B1 (enExample) |
| SG (1) | SG11201803324VA (enExample) |
| SI (1) | SI3365366T1 (enExample) |
| TW (3) | TW202442675A (enExample) |
| UY (1) | UY36965A (enExample) |
| WO (1) | WO2017074878A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| WO2015128846A1 (en) * | 2014-02-28 | 2015-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region |
| ES2894304T3 (es) * | 2015-10-25 | 2022-02-14 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH |
| EP4011911A1 (en) * | 2015-11-03 | 2022-06-15 | The United States of America as represented by The Secretary Department of Health and Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
| EP3443006B1 (en) | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| MY192090A (en) * | 2016-04-13 | 2022-07-26 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| KR102654105B1 (ko) | 2017-02-17 | 2024-04-04 | 사노피 | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
| EP3601334A4 (en) * | 2017-03-27 | 2021-03-31 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
| JP7009517B2 (ja) | 2017-06-21 | 2022-01-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体 |
| CN111788225B (zh) | 2017-10-10 | 2025-02-18 | 赛诺菲 | 抗cd38抗体及与抗cd3和抗cd28抗体的组合 |
| WO2019123262A1 (en) * | 2017-12-18 | 2019-06-27 | VIIV Healthcare UK (No.5) Limited | Antigen binding polypeptides |
| CN111819196B (zh) * | 2017-12-21 | 2022-10-28 | 纽约市哥伦比亚大学理事会 | 双特异性hiv-1中和抗体 |
| IL275536B2 (en) | 2018-01-12 | 2025-06-01 | Genzyme Corp | Methods for quantification of polypeptides |
| EP3797118A4 (en) | 2018-05-22 | 2022-06-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| TWI856979B (zh) * | 2018-10-09 | 2024-10-01 | 法商賽諾菲公司 | 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法 |
| EP3883962A4 (en) * | 2018-11-21 | 2023-04-12 | Beth Israel Deaconess Medical Center, Inc. | ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) |
| TW202104274A (zh) * | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白 |
| JP7664175B2 (ja) * | 2019-04-09 | 2025-04-17 | サノフイ | 三重特異性結合性タンパク質、方法、およびその使用 |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| MX2022004881A (es) | 2019-10-25 | 2022-05-16 | Sanofi Sa | Metodos para analizar el emparejamiento incorrecto de cadenas en proteinas de union multiespecificas. |
| US20230203466A1 (en) * | 2020-04-03 | 2023-06-29 | Medgenome Inc. | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
| JP7518286B2 (ja) * | 2020-08-25 | 2024-07-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法 |
| EP4408892A4 (en) * | 2021-09-29 | 2025-11-19 | Modex Therapeutics Inc | Antigen-binding polypeptides, antigen-binding polypeptide complexes, and their methods of use in HIV |
| TW202330594A (zh) * | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| CN118317979A (zh) * | 2021-09-29 | 2024-07-09 | 摩德斯医疗股份有限公司 | 抗原结合多肽、抗原结合多肽复合物及其使用方法 |
| AU2024386429A1 (en) | 2023-11-22 | 2026-05-21 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| AU2023474055A1 (en) | 2023-11-23 | 2026-06-04 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| WO2025238419A1 (en) | 2024-05-17 | 2025-11-20 | Sanofi | Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| EP1361892A4 (en) | 2001-01-17 | 2004-10-13 | Trubion Pharmaceuticals Inc | BINDING DOMAIN FUSION PROTEIN Immunoglobulin |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| US9175070B2 (en) | 2009-09-25 | 2015-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| CN103282385A (zh) | 2010-11-12 | 2013-09-04 | 美国洛克菲勒大学 | 用于hiv治疗的融合蛋白 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| CN112225798B (zh) * | 2011-05-17 | 2023-07-18 | 洛克菲勒大学 | 人类免疫缺陷病毒中和抗体及其使用方法 |
| CN103906533A (zh) * | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| CN104080805B (zh) | 2011-11-07 | 2017-02-22 | 美国政府健康及人类服务部 | gp41中和性抗体及其用途 |
| CN104271597B (zh) | 2011-12-08 | 2018-05-25 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
| WO2013163427A1 (en) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US20150239991A1 (en) * | 2012-09-25 | 2015-08-27 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| CN104955847A (zh) | 2012-12-04 | 2015-09-30 | 马里兰州大学(巴尔的摩) | HIV-1 Env结合抗体、融合蛋白及其使用方法 |
| EP2931318A4 (en) | 2012-12-13 | 2016-07-20 | Univ Pennsylvania | DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF |
| US20140213772A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| CN110437337B (zh) * | 2013-02-26 | 2024-07-30 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| CA2904407A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | Dual specific binding proteins directed against tnf.alpha. |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| AP2016009222A0 (en) | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| BR112017004270B1 (pt) | 2014-09-04 | 2023-03-07 | Stemcell Technologies Inc | Método de ativação de células t ou células nk |
| AR103488A1 (es) | 2015-01-23 | 2017-05-10 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| TWI704229B (zh) | 2015-05-20 | 2020-09-11 | 美商寬騰矽公司 | 核酸定序方法 |
| WO2016196740A1 (en) | 2015-06-02 | 2016-12-08 | The Rockefeller University | Tri-specific antibodies for hiv therapy |
| JP6991131B2 (ja) | 2015-09-22 | 2022-02-03 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｈｉｖ感染症を処置するためにｔ細胞を再度方向付ける方法 |
| ES2894304T3 (es) | 2015-10-25 | 2022-02-14 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH |
| CN105837688B (zh) | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 |
| JP6732915B2 (ja) | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ， インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| MY192090A (en) | 2016-04-13 | 2022-07-26 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
| EP3443006B1 (en) | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| EP3575319A4 (en) | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | BIFUNCTIONAL MOLECULE AND USE OF IT |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| KR102654105B1 (ko) | 2017-02-17 | 2024-04-04 | 사노피 | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
| EP3601334A4 (en) | 2017-03-27 | 2021-03-31 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
| CN111788225B (zh) | 2017-10-10 | 2025-02-18 | 赛诺菲 | 抗cd38抗体及与抗cd3和抗cd28抗体的组合 |
| TWI856979B (zh) | 2018-10-09 | 2024-10-01 | 法商賽諾菲公司 | 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法 |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2016
- 2016-10-24 ES ES16794472T patent/ES2894304T3/es active Active
- 2016-10-24 SI SI201631358T patent/SI3365366T1/sl unknown
- 2016-10-24 PL PL16794472T patent/PL3365366T3/pl unknown
- 2016-10-24 CA CA3002664A patent/CA3002664A1/en active Pending
- 2016-10-24 MA MA42641A patent/MA42641A1/fr unknown
- 2016-10-24 EP EP16794472.7A patent/EP3365366B1/en active Active
- 2016-10-24 EP EP20197556.2A patent/EP3819310A1/en active Pending
- 2016-10-24 RS RS20211266A patent/RS62437B1/sr unknown
- 2016-10-24 AU AU2016347058A patent/AU2016347058B2/en active Active
- 2016-10-24 JP JP2018521308A patent/JP7169190B2/ja active Active
- 2016-10-24 HR HRP20211528TT patent/HRP20211528T1/hr unknown
- 2016-10-24 IL IL301140A patent/IL301140A/en unknown
- 2016-10-24 EA EA201891028A patent/EA201891028A1/ru unknown
- 2016-10-24 HU HUE16794472A patent/HUE056608T2/hu unknown
- 2016-10-24 CN CN202310185803.8A patent/CN117069855A/zh active Pending
- 2016-10-24 SG SG11201803324VA patent/SG11201803324VA/en unknown
- 2016-10-24 CN CN201680075852.4A patent/CN109311966B/zh active Active
- 2016-10-24 CN CN202310186776.6A patent/CN116789841A/zh active Pending
- 2016-10-24 BR BR112018008011-0A patent/BR112018008011A2/en not_active Application Discontinuation
- 2016-10-24 MX MX2018005048A patent/MX2018005048A/es unknown
- 2016-10-24 KR KR1020187014534A patent/KR102687212B1/ko active Active
- 2016-10-24 MY MYPI2018701634A patent/MY192278A/en unknown
- 2016-10-24 PE PE2018000603A patent/PE20181167A1/es unknown
- 2016-10-24 US US15/770,471 patent/US20190054182A1/en not_active Abandoned
- 2016-10-24 CR CR20180288A patent/CR20180288A/es unknown
- 2016-10-24 WO PCT/US2016/058540 patent/WO2017074878A1/en not_active Ceased
- 2016-10-24 CN CN202310147287.XA patent/CN116675776A/zh active Pending
- 2016-10-25 TW TW113100534A patent/TW202442675A/zh unknown
- 2016-10-25 AR ARP160103249A patent/AR106466A1/es unknown
- 2016-10-25 UY UY0001036965A patent/UY36965A/es not_active Application Discontinuation
- 2016-10-25 TW TW105134405A patent/TWI750139B/zh active
- 2016-10-25 TW TW110126977A patent/TW202219064A/zh unknown
-
2018
- 2018-04-20 DO DO2018000102A patent/DOP2018000102A/es unknown
- 2018-04-22 IL IL258822A patent/IL258822B2/en unknown
- 2018-04-23 CL CL2018001065A patent/CL2018001065A1/es unknown
- 2018-04-23 PH PH12018500873A patent/PH12018500873A1/en unknown
- 2018-04-24 MX MX2022014631A patent/MX2022014631A/es unknown
- 2018-05-22 CO CONC2018/0005337A patent/CO2018005337A2/es unknown
-
2019
- 2019-10-21 US US16/659,426 patent/US11129905B2/en active Active
-
2021
- 2021-02-04 JP JP2021016190A patent/JP7328267B2/ja active Active
- 2021-08-17 US US17/404,908 patent/US11779651B2/en active Active
-
2023
- 2023-04-06 JP JP2023061823A patent/JP7724814B2/ja active Active
-
2024
- 2024-01-22 AU AU2024200395A patent/AU2024200395A1/en active Pending
- 2024-11-26 US US18/960,890 patent/US20250312475A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250312475A1 (en) | Bivalent, bispecific binding proteins for prevention or treatment of hiv infection | |
| JP7462621B2 (ja) | 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法 | |
| US20250250337A1 (en) | Trispecific binding proteins, methods, and uses thereof | |
| CA3065328C (en) | Multispecific antibodies that target hiv gp120 and cd3 | |
| CN113950484B (zh) | 三特异性结合蛋白、其方法和用途 | |
| CA3136147A1 (en) | Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection | |
| RU2822200C2 (ru) | Триспецифические связывающие белки, относящиеся к ним способы и варианты их применения | |
| HK40098941A (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| HK40100590A (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv | |
| HK40052791A (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| HK1253385B (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| EA040589B1 (ru) | Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv |